Feedback
Settings

Settings

Goto Application

1. WO2020221294 - BRIDGE RING-3,4-DIHYDRO-PYRIDO[1,2-A]PYRAZINE-1,8-DIONE COMPOUND AND PHARMACEUTICAL USE THEREOF

PermaLink
Publication Number WO/2020/221294
Publication Date 05.11.2020
International Application No. PCT/CN2020/087774
International Filing Date 29.04.2020
IPC
C07D 471/00 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
471Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/-C07D463/251
C07D 487/00 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
487Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/-C07D477/183
A61K 31/4985 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/55 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
55having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61P 31/18 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
18for HIV
CPC
A61K 31/4985
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two ; or more; nitrogen atoms as the only ring heteroatoms, e.g. piperazine ; or tetrazines
4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/55
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
55having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61P 31/18
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
18for HIV
C07D 471/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
471Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
C07D 487/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
487Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00
Y02P 20/55
YSECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
20Technologies relating to chemical industry
50Improvements relating to the production of bulk chemicals
55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Applicants
  • 上海拓界生物医药科技有限公司 TUOJIE BIOTECH (SHANGHAI) CO., LTD. [CN]/[CN]
Inventors
  • 祝伟 ZHU, Wei
  • 连韶 LIAN, Shao
  • 刘彪 LIU, Biao
  • 王元昊 WANG, Yuanhao
  • 余健 YU, Jian
  • 邹昊 ZOU, Hao
  • 李正涛 LI, Zhengtao
Agents
  • 北京戈程知识产权代理有限公司 GE CHENG & CO., LTD
Priority Data
201910359186.230.04.2019CN
201910862609.212.09.2019CN
Publication Language Chinese (zh)
Filing Language Chinese (ZH)
Designated States
Title
(EN) BRIDGE RING-3,4-DIHYDRO-PYRIDO[1,2-A]PYRAZINE-1,8-DIONE COMPOUND AND PHARMACEUTICAL USE THEREOF
(FR) COMPOSÉ DE 3,4-DIHYDRO-PYRIDO[1,2-A]PYRAZINE-1,8-DIONE CYCLIQUE EN PONT ET SON UTILISATION PHARMACEUTIQUE
(ZH) 桥环-3,4-二氢-吡啶并[1,2-a]吡嗪-1,8-二酮化合物及其药物用途
front page image
Abstract
(EN) A bridge ring-3,4-dihydro-pyrido[1,2-a]pyrazine-1,8-dione compound and a pharmaceutical use thereof. Specifically provided are the compound shown in formula I or a pharmaceutically acceptable salt or stereoisomer, rotamer, or tautomer thereof, wherein R1-R8 are as defined in the present text. The compound shown in formula I can be used for the treatment of human immunodeficiency virus (HIV) infection.
(FR) L'invention concerne un composé de 3,4-dihydro-pyrido [1,2-a]pyrazine-1,8-dione cyclique en pont et son utilisation pharmaceutique. L'invention concerne spécifiquement le composé représenté par la formule I ou un sel ou stéréoisomère, rotamère, ou tautomère pharmaceutiquement acceptable de celui-ci, R1-R8 étant tels que définis dans lla description. Le composé représenté dans la formule I peut être utilisé pour le traitement d'une infection par le virus de l'immunodéficience humaine (VIH).
(ZH) 一种涉及桥环-3,4-二氢-吡啶并[1,2-a]吡嗪-1,8-二酮化合物及其药物用途。具体而言，提供一种式I所示化合物或其可药用的盐或其立体异构体、旋转异构体或互变异构体，其中R 1-R 8如本文定义的。所述式I所示化合物可用于治疗人类免疫缺陷病毒(HIV)感染。
Related patent documents
CN113795491
Latest bibliographic data on file with the International Bureau
# -